Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine

Journal of Controlled Release

Volumn 140, Issue 2, 2009, Pages 157-165

  Tiwari, Shailja ^a   Goyal, Amit K ^a   Mishra, Neeraj ^a   Khatri, Kapil ^a   Vaidya, Bhuvaneshwar ^a   Mehta, Abhinav ^a   Wu, Yimin ^b   Vyas, Suresh P ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

CpGODN; Gel core liposomes; Pfs25; Poly acrylic acid; Vaccine adjuvant

Indexed keywords

ANTIBODY TITERS; BALB/C MICE; BIOCOMPATIBLE POLYMER; CPGODN; EFFECT OF CO; EVAPORATION METHOD; HIGH POTENTIAL; IMMUNE RESPONSE; IMMUNOGENICITY; IN-PROCESS; IN-VITRO; INTRAMUSCULAR ADMINISTRATION; MALARIA VACCINE; PFS25; PHOSPHOLIPID BILAYER; POLY ACRYLIC ACID; POLYACRYLIC ACIDS; POTENTIAL UTILITY; RECOMBINANT PROTEIN; REVERSE PHASE; SDS-PAGE; WESTERN BLOTTING;

ANTIGENS; CARBOXYLIC ACIDS; DIFFUSERS (OPTICAL); GELATION; GELS; LIPOSOMES; ORGANIC ACIDS; VACCINES;

PHOSPHOLIPIDS;

CPG OLIGODEOXYNUCLEOTIDE; DRUG CARRIER; GEL CORE LIPOSOME; LIPOSOME; MALARIA VACCINE; POLYACRYLIC ACID; RECOMBINANT PFS25 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BIOCOMPATIBILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENTIATION; DRUG STABILITY; DRUG STORAGE; ENCAPSULATION; EVAPORATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOSTIMULATION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PHOSPHOLIPID BILAYER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ACRYLIC RESINS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; BLOTTING, WESTERN; CHEMISTRY, PHARMACEUTICAL; CYTOKINES; DRUG COMPOUNDING; DRUG STORAGE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GELS; INJECTIONS, INTRAMUSCULAR; LIPOSOMES; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PARTICLE SIZE; PHOSPHOLIPIDS; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTOZOAN PROTEINS; VACCINES, SYNTHETIC;

EID: 70350617699     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.08.004     Document Type: Article

References (51)

1. Butler D., Maurice J., and Brien C.O. Time to put malaria control on the global agenda. Nature 386 (1997) 535-540
2. Targett G.A.T. Status of malaria vaccine research. Journal of the Royal Society of Medicine 82 17 (1989) 52-56
3. Targett G.A. Malaria vaccines 1985-2005:a full circle. Trends in Parasitology 21 11 (2005) 499-503
4. Miller L.H., and Hoffman S.L. Research towards vaccine against malaria. Nature Medicine Vaccine supplimant 4 5 (1988) 520-524
5. Storni T., Kundig T.M., Senti G., and Johansen P. Immunity in response to particulate antigen-delivery systems. Advanced Drug Delivery Reviews 57 3 (2005) 333-355
6. Yoshikawa T., Imazu S., Gao J.Q., Hayashi K., Tsuda Y., and Shimokawa M. Augmentation of antigen-specific immune responses using DNA-fusogenic liposome vaccine. Biochemical and Biophysical Research Communications 325 (2004) 500-505
7. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Mehta A., and Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 26 (2008) 2225-2233
8. Alving C.R., Banerji B., Shiba T., Kotani S., Clements J.D., and Richards R.L. Liposomes as vehicles for vaccines. Progress in Clinical and Biological Research 47 (1980) 339-355
9. Gregoriadis G., McCormack B., Obrenovic M., Perrie Y., and Saffie R. Liposomes as immunological adjuvants and vaccine carriers. Methods in Molecular Medicine 42 (2000) 137-150
10. Ketloy C., Engering A., Srichairatanakul U., Limsalakpetch A., Yongvanitchit K., Pichyangkul S., and Ruxrungtham K. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates. Veterinary Immunology and Immunopathology 125 (2008) 18-30
11. Takahir S., Katsuaki H., Masuyoshi S., Takahiro Y., Izumi S., Chihiro Y., Shizuo A., and Tsuneyasu K. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. International Immunology 20 1 (2008) 1-9
12. Garlapati S., Facci M., Polewicz M., Strom S., Babiuk L.A., Mutwiri G., Hancock R.E.W., Elliott M.R., and Gerdts V. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Veterinary Immunology and Immunopathology 128 1-3 (2009) 184-191
13. Gozar M.M.G., Muratova O., Keister D.B., Kensil C.R., Price V.L., and Kaslow D.C. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Experimental Parasitology 97 2 (2001) 61-69
14. LeBlanc R., Vasquez Y., Hannaman D., and Kumar N. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation. Vaccine 26 2 (2008) 185-192
15. Zou L., Miles A.P., Wang J., and Stowers A.W. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 21 15 (2003) 1650-1657
16. Cohen S., Bernstein H., Hewes C., Chow M., and Langer R. The pharmacokinetics of, and humoral responses to, antigen delivered by microencapsulated liposomes. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 10440-10444
17. Feng S.S., Ruanb G., and Lic Q.T. Fabrication and characterizations of a novel drug delivery device liposomes-in-microsphere (LIM). Biomaterials 25 (2004) 5181-5189
18. Schnurch A.B., Egger C., Elhassan Imam M., and Krauland A.H. Preparation and in vitro characterization of poly (acrylic acid)-cysteine microparticles. Journal of Controlled Release 93 10 (2003) 29-38
19. Bibby D.C., Davies N.M., and Tucker I.G. Poly(acrylic acid) microspheres containing β-cyclodextrin: loading and in vitro release of two dyes. International Journal of Pharmaceutics 187 (1999) 243-250
20. MacLean D.S., Robertson J.S., Jay M., and Stalker D.J. Noninvasive measurement of protein release from subcutaneous depo formulations in vivo using X-ray fluorescence. Journal of Controlled Release 34 2 (1995) 167-173
21. Topuzogullar M., Çimen N.S., Mustafaeva Z., and Mustafaev M. Molecular-weight distribution and structural transformation in water-soluble complexes of poly(acrylic acid) and bovine serum albumin. European Polymer Journal 43 7 (2007) 2935-2946
22. 2+-mediated polyanion-protein complex-antigen specificity and affinity of hybridoma clones. Immunology Letters 52 (1996) 63-68
23. Chuna M., Sah H., and Choi H.K. Preparation of mucoadhesive microspheres containing antimicrobial agents for eradication of H. pylori. International Journal of Pharmaceutics 297 (2005) 172-179
24. Tiwari S., Goyal A., Khatri K., Mishra N., and Vyas S.P. Gel core liposomes: an advanced carrier for improved vaccine delivery. Journal of Microencapsulation 26 1 (2009) 75-82
25. Coban C., Ishii K.J., Stowers A.W., Keister D.B., Klinman D.M., and Kumar N. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25,a Plasmodium falciparum transmission-blocking vaccine antigen. Infection and Immunity 72 1 (2004) 584-588
26. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 (1999) 19-25
27. McCluskie M.J., and Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. Journal of Immunology 161 (1998) 4463-4469
28. Moldoveanu Z., Love-Homan L., Huang W.Q., and Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 (1998) 1216-1224
29. Chu R.S., Targoni O.S., Krieg A.M., Lehmann P.V., and Harding C.V. CpG oligodeoxynucleotides act as adjuvants that switch on T helper1 (Th1) immunity. Journal of Experimental Medicine 186 (1997) 1623-1631
30. Jones T.R., Obaldia N., Gramzinski R.A., Charoenvit Y., Kolodny N., Kitov S., Davis H.L., Krieg A.M., and Hoffman S.L. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17 (1999) 3065-3071
31. Krieg A.M. CpG motifs: the active ingredient in bacterial extracts. Nature Medicine 9 (2003) 831-835
32. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G., and Klinman D. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1996) 546-549
33. Klinman D.M., Yi A.L., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFN-γ. Proceedings of the National Academy of Sciences 93 (1996) 2879-2883
34. Cowdery J.S., Chace J.H., Yi A.K., and Krieg A.M. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. Journal of Immunology 156 (1996) 4570-4575
35. Weeratna R.D., McCluskie M.J., Xu Y., and Davis H.L. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18 (2000) 1755-1762
36. Sazoka F.C., and Papahadjopoulos D. Procedure for the preparation of liposomes with large aqueous space and high capture by reverse-phase evaporation. Proceedings of the National Academy of Sciences of the United States of America 75 (1978) 4194-4198
37. Li W.M., Dragowska W.H., Bally M.B., and Schutze-Redelmeier M.P. Effective induction of CD8+ T cell response using CpG oligodeoxynucleotides and HER-3/neu-derived peptide co-encapsulated in liposomes. Vaccine 21 (2003) 3319-3329
38. Jaganathan K.S., and Vyas S.P. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24 (2006) 4201-4211
39. Scholz S.M., Simon N., Lavazec C., Dude M.A., Templeton T.J., and Pradel G. PfCCp proteins of Plasmodium falciparum: gametocyte-specific expression and role in complement-mediated inhibition of exflagellation. International Journal for Parasitology 38 (2008) 327-340
40. Sachdeva S., Ahmad G., Malhotra P., Mukherjee P., and Chauhan V.S. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 119 and 42 kDa fragments expressed in Escherichia coli. Infection and Immunity 70 10 (2004) 5775-5785
41. Wu Y., Ellis R.D., Shaffer D., Fontes E., Malkin E.M., Mahanty S., Fay M.P., Narum D., Rausch K., Miles A.P., Aebig J., Orcutt A., Muratova O., Song G., Lambert L., Zhu D., Miura K., Long C., Saul A., Miller L.H., and Durbin A.P. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. Plosone 3 7 (2008) 2636
42. Dai C., Wang H., Zhao L.B., and Wang J. Preparation and characterization of liposomes-in-alginate (LIA) for protein delivery system. Colloids and Surfaces. B, Biointerfaces 47 (2006) 205-210
43. Torchilin V.P., Schlarb B., Klibanov L., Ivanov N., and Ringsdorf H. Liposome-polymer systems. Introduction of liposomes into polymer gel and preparation of polymer gel inside into liposome. Polymer sciences. USSR 30 10 (1988) 2307-2312
44. Torchllin V.P., Klibanov L., and Ivanov N. Polymerization of liposome-encapsulated hydrophilic monomers. Makromolekulare Chemie. Rapid Communications 8 (1987) 457-460
45. Fogg C.N., Americo J.L., Lustig S., Huggins J.W., Smith S.K., Damon I., Resch W., Earl P.L., Klinman D.M., and Moss B. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25 (2007) 2787-2799
46. Mullen G.E., Giersing B.K., Ajose-Popoola O., Davis H.L., Kothe C., Zhou H., Aebig J., Dobrescu G., Saul A., and Long C.A. Enhancement of functional antibody responses to AMA1-C1/alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24 14 (2006) 2497-2505
47. Hirunpetcharat C., Wipasa J., Sakkhachornphop S., Nitkumhan T., Zheng Y.Z., Pichyangkul S., Krieg A.M., Walsh D.S., Heppner D.G., and Good M.F. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP119) formulated in oil-based Montanides. Vaccine 21 (2003) 2923-2932
48. Shirota H., Sano K., Hirasawa N., Terui T., Ohuchi K., Hattori T., and Tamura G. B cell capturing antigen conjugated with CpG oligodeoxynucleotides induced Th1 cells by elaborating IL-12. Journal of Immunology 169 (2002) 787-794
49. Jaio X., Wang R.Y.H., Qiu Q., Alter H.J., and Shih J.W. Enhanced hepatits C virus NS3 specific Th1 immune response induced by co-delivery of protein antigen and CpG with cationic liposomes. Journal of General Virology 85 (2004) 1545-1553
50. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., Wagner H., Takeda K., and Akira S. A toll like receptor recognizes bacterial NA. Nature 408 (2000) 740-750
51. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., and Wagner H. Bacterial CpG-DNA and lipopolysaccharide activate toll like receptor at distinct cellular compartments. European Journal of Immunology 32 (2002) 1958-1968